Kashiv BioSciences Private Limited has secured ₹648 crore in financing from the Union Bank of India to support the expansion of its advanced manufacturing facility in Pipan, near Ahmedabad, Gujarat. The funding will be used to build a new single-use commercial biomanufacturing facility, which will rank among the largest of its kind in India.
Equipped with state-of-the-art technologies, the facility will support the production of high-quality biologics and specialty pharmaceuticals. Once fully operational, Kashiv expects the plant to have a manufacturing capacity of up to 50,000 liters.
This expansion represents a significant milestone in Kashiv’s growth strategy, strengthening both its global presence and India’s role as a hub for advanced biopharmaceutical manufacturing. The facility will serve customers across the United States, Canada, Europe, and other international markets, while generating long-term, high-value employment in scientific, technical, and operational roles.
Dr Sandeep Athalye, Global CEO of Kashiv BioSciences, said “This financing marks a transformative moment for Kashiv as we scale our biomanufacturing capabilities in India. The Pipan facility will accelerate innovation, improve access to high-quality biologics, and reinforce our commitment to building world-class infrastructure that supports global healthcare. The project is supported by Union Bank of India and aligns with Gujarat’s Biotechnology Policy and initiatives led by the Gujarat State Biotechnology Mission.”
Digvijaysinh D Jadeja, IAS, Mission Director of the Gujarat State Biotechnology Mission (GSBTM), stated:
“Kashiv’s expansion highlights Gujarat’s focus on innovation-driven growth in biotechnology. Through our policy framework, we continue to encourage investments that enhance India’s scientific capabilities and create meaningful employment opportunities.”
A senior representative from Union Bank of India added “Union Bank is pleased to support Kashiv in this important initiative. The project will strengthen India’s manufacturing ecosystem and contribute to sustainable economic development, supporting the national vision of a self-reliant and developed India.”
Kashiv BioSciences Private Limited, a wholly owned subsidiary of Kashiv BioSciences, LLC, is a biopharmaceutical company with multiple commercial and late-stage clinical assets. The organization is among a select group globally that has both manufactured biosimilars and obtained marketing approvals for them.
Operating across the United States and India, Kashiv combines global R&D, clinical development, manufacturing, regulatory, and intellectual property expertise. The company is driven by a shared mission to expand patient access to critical medicines through innovation and collaboration.